drugset

drugset / Trial / NCT02685046

Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy

NCT02685046 ↗

Phase 2 Terminated 5 enrolled UMC Utrecht Erasmus Medical Center · collab Hubrecht Institute · collab Meander Medical Center · collab

NaSingle-groupOpen-labelTreatment

Summary

In this proof-of-concept trial the investigators will study the effects of imatinib treatment on the biology of mesenchymal-type colon cancers.

Timeline

Start: 2016-04
Primary completion: 2019-09-01
Completion: 2019-09-01

Outcome

Outcome not reported

Stopped (Enrollment): “Low accrual rate”

Publications

Ubink I, Bloemendal HJ, Elias SG, Brink MA, Schwartz MP, Holierhoek YCW, Verheijen PM, Boerman AW, Mathijssen RHJ, de Leng WWJ, de Weger RA, van Grevenstein WMU, Koopman M, Lolkema MP, Kranenburg O, Borel Rinkes IHM. Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT). BMC Cancer. 2017 Apr 19;17(1):282. doi: 10.1186/s12885-017-3264-y.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Imatinib	Small molecule	400 mg	Oral

Indications